Skip to main content
eScholarship
Open Access Publications from the University of California
Refine Search

Medical Student Research Forum Posters

UC Davis

How Do FDA approved Biologics Compare to Narrow-Band Ultra-Violet B Light for the treatment of moderate to severe Psoriasis and AtopicDermatitis?

The data associated with this publication are not available for this reason: N/A
Abstract

One percent to 3% of adults worldwide are impacted by psoriasis. 2% of US adults are impacted by atopic dermatitis. Psoriasis and atopic dermatitis are chronic illnesses with compounding costs of treatment. Biologics are desirable treatments for moderate to severe psoriasis and atopic dermatitis. Purpose: Provide a cost benefit analysis of all biologics compared to narrow band ultraviolet B(NVUVB) light therapy for the management of atopic dermatitis and psoriasis.

Main Content
For improved accessibility of PDF content, download the file to your device.


Top